(Total Views: 284)
Posted On: 06/15/2021 9:24:41 AM
Post# of 48
ONCOTELIC CLOSES COVID-19 CLINICAL TRIAL EARLY
Link to press release
Link to press release
Quote:
“Due to the continuing rise of more severe variants in Latin America, leading to exhaustion of medical care infrastructure in Latin America, Oncotelic chose to stop enrollment before full enrollment of the 18 patients needed for Part 2 so that we can unblind the trial to determine the role of TGF-beta in the variants currently dominant in Latin America. This will provide us with an opportunity to assess our corporate directions as to COVID.”, said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)